Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

20141,604 citationsJournal Articlebronze Open Access

Authors

Guy Meyer

Éric Vicaut · Université Paris Cité

Thierry Danays · Boehringer Ingelheim (France)

Giancarlo Agnelli · University of Perugia

Cecilia Becattini · University of Perugia

Jan Beyer‐Westendorf · University Hospital Carl Gustav Carus

Erich Bluhmki · Boehringer Ingelheim (Egypt)

Abstract

In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Acute Myocardial Infarction Research Atrial Fibrillation Management and Outcomes

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 15, pp. 1402-1411

DOI: 10.1056/nejmoa1302097

Field-Weighted Citation Impact: 94.09